By: IPP Bureau
Last updated : December 15, 2021 9:29 am
The cash consideration for the acquisition is US$ 18 million.
NATCO Pharma is set to acquire Dash Pharmaceuticals. Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of US $ 15 million for the year ending December 2021.
This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.
The cash consideration for the above acquisition is US$ 18 million.